Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Shire    SHP   JE00B2QKY057

SHIRE (SHP)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 09/21 05:35:01 pm
4569 GBp   +1.33%
09/21SHIRE : Form 8.3 - Takeda Pharmaceutical Company Limited
PU
09/21SHIRE : Form 8.5 (EPT/RI) - SHIRE PLC
PU
09/21SHIRE : Form 8.3 - Shire plc
PU
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

SHIRE : Ex-dividend day for final dividend

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/08/2018 CEST

A final dividend is removed today from Shire's share.



© Factset 2018
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SHIRE
09/21SHIRE : Form 8.3 - Takeda Pharmaceutical Company Limited
PU
09/21SHIRE : Form 8.5 (EPT/RI) - SHIRE PLC
PU
09/21SHIRE : Form 8.3 - Shire plc
PU
09/21MERRIMACK PHARMACEUTICALS : Receives $5 Million Milestone Payment from Shire
AQ
09/21SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
09/21SHIRE : Receives Approval of FIRAZYR(R) (icatibant injection) for the Treatment ..
PU
09/21SHIRE PLC : Rule 2.9 Announcement
PU
09/21SHIRE : Receives Approval of FIRAZYR® (icatibant injection) for the Treatment of..
AQ
09/20SHIRE : Form 8 (DD) - Citibank NA London
PU
09/20SHIRE : Form 8 (DD) - Citibank NA Switzerland
PU
More news
News from SeekingAlpha
09/21A Deeper Dive Into Sibanye-Stillwater + A Few Updates 
09/21Protalix up 20% on positive PRX-102 data in Fabry 
09/21Key events next week - healthcare 
09/21Shire's Firazyr OK'd Japan for HAE attacks 
09/17House nixes drug prices in TV ads 
Financials ($)
Sales 2018 15 527 M
EBIT 2018 5 896 M
Net income 2018 2 730 M
Debt 2018 15 199 M
Yield 2018 0,61%
P/E ratio 2018 18,52
P/E ratio 2019 16,05
EV / Sales 2018 4,55x
EV / Sales 2019 4,19x
Capitalization 55 437 M
Chart SHIRE
Duration : Period :
Shire Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHIRE
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 65,0 $
Spread / Average Target 8,8%
EPS Revisions
Managers
NameTitle
Flemming Ornskov Chief Executive Officer
Susan Saltzbart Kilsby Non-Executive Chairman
Thomas J. W. Dittrich Chief Financial Officer & Director
Howard Mayer Chief Medical Officer
Matthew Walker Head-Technical Operations
Sector and Competitors
1st jan.Capitalization (M$)
SHIRE17.15%55 437
JOHNSON & JOHNSON1.62%383 312
PFIZER21.65%258 285
NOVARTIS-0.63%216 108
ROCHE HOLDING LTD.-4.60%211 501
MERCK AND COMPANY25.79%189 092